Surgery Partners (SGRY) EBITDA Margin (2014 - 2026)

Surgery Partners has disclosed EBITDA Margin across 13 years of filings, most recently posting 8.11% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 8.11%, up 14.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 11.77% (up 122.0% YoY), and the FY2025 annual result was 16.92%, up 107.0% from the prior year.
• EBITDA Margin came in at 8.11% for Q1 2026 at Surgery Partners, down from 12.45% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 16.84% in Q1 2022 to a low of 6.96% in Q1 2023.
• The 5-year median for EBITDA Margin is 12.43% (2022), against an average of 11.85%.
• Across the five-year window, EBITDA Margin sank 988 bps in 2023 and jumped 496 bps in 2025, its largest moves.
• Surgery Partners' EBITDA Margin stood at 13.32% in 2022, then climbed by 4 bps to 13.79% in 2023, then advanced by 7 bps to 14.7% in 2024, then fell by 15 bps to 12.45% in 2025, then plunged by 35 bps to 8.11% in 2026.
• The last three EBITDA Margin figures came in at 8.11% (Q1 2026), 12.45% (Q4 2025), and 12.87% (Q3 2025), per Business Quant data.